Sequence 23 from Patent US 20060122119

General Information


DRACP ID  DRACP01255

Peptide Name   Sequence 23 from Patent US 20060122119

Sequence  EAAGIGILT

Sequence Length  9

UniProt ID  Q16655 

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01255

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C37H65N9O13

Absent amino acids  CDFHKMNPQRSVWY

Common amino acids  AGI

Mass  98687

Pl  3.85

Basic residues  0

Acidic residues  1

Hydrophobic residues  5

Net charge  -1

Boman Index  1088

Hydrophobicity  126.67

Aliphatic Index  152.22

Half Life 
  Mammalian: 1 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2006/0122119 A1

Patent Title  Peptides for use in antitumor immunotherapy.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002

Other Published ID  CA2477762A1  EP1481009A2  WO2003074565A2  WO2003074565A3 




DRACP is developed by Dr.Zheng's team.